Moderna turns focus to RSV vaccine race after Q1 profit beat


The drugmaker brought in more sales revenue from its Covid-19 vaccines than expected in the first quarter.

Previous J&J consumer products spinoff Kenvue goes public through $3.8B IPO
Next 'Not a campaign': Anheuser-Busch InBev CEO downplays Dylan Mulvaney controversy, says company will triple Bud Light spending